title: Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm.
abstract: Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.
authors.affiliation: Division of Cell and Molecular Biology, Toronto General Research Institute, Toronto, ON M5G 1L7, Canada. jwang@uhnres.utoronto.ca
authors.forename: Jean C Y
authors.initials: JC
authors.lastname: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D016923:Cell Death; D002469:Cell Separation; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018365:Neoplasm, Residual; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D012008:Recurrence; D012107:Research Design; D013234:Stem Cells / Q000187:drug effects; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor